Jayne Prats, PhD

Dr. Prats is an Executive Consultant at ELYSIS-Med Scientific Solutions, where she has worked with biotech and pharma companies including Chiesi, PLx Pharma, Vero Biotech, Arch Therapeutics, and PhaseBio. Dr Prats was VP in the Acute Cardiovascular Care group at The Medicines Company, with responsibility for thrombosis and vascular biology programs for the company’s antithrombotic drugs. During her time at The Medicines Company, she was a key contributor to clinical trial and regulatory efforts that culminated in the successful approval of drugs in the US, European Union, Asia and other international jurisdictions. Dr. Prats developed knowledge management programs for antithrombotic drugs as well as for The Medicines Company’s hemostatic and acute pain control devices, and anti-infective agents.

Dr. Prats has co-authored over 75 scientific publications, including journal articles, reviews, patents, and book chapters on the topics relating to thrombosis and vascular biology, clinical trials in interventional cardiology, platelets, clotting disorders, and atherosclerosis. She is a member of the International Society on Thrombosis and Haemostasis, the American Heart Association, and the American College of Cardiology. Dr. Prats earned a BS in Chemistry from the University of Massachusetts, Amherst, and a PhD in Biochemistry from Boston University School of Medicine.